PLAU/uPA (active form), His, Cynomolgus
PLAU/uPA (active Form), His, Cynomolgus

Immobilized PLAU/uPA (active form), His, Cynomolgus, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Human uPAR, hFc Tag with the EC50 of 21.4ng/ml determined by ELISA.

PLAU/uPA (active Form), His, Cynomolgus

The purity of PLAU/uPA (active form), His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

PLAU/uPA (active Form), His, Cynomolgus

PLAU/uPA (active form), His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

PLAU/uPA (active Form), His, Cynomolgus

Cynomolgus uPAR, His Tag immobilized on CM5 Chip can bind PLAU/uPA (active form), His, Cynomolgus, His Tag with an affinity constant of 0.033 nM as determined in SPR assay (Biacore T200).

PLAU/uPA (active form), His, Cynomolgus

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Z04898
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
PLAU/uPA (Ser21-Leu430)
Accession # A0A2K5WND1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. Measured by its ability to cleave a peptide substrate,N­carbobenzyloxy­Gly­Gly­Arg­7­amido­4­methylcoumarin (ZGGR­AMC). Test result meets the standard.
Expression System HEK293
Theoretical Molecular Weight 47.23 kDa
Apparent Molecular Weight Due to protein lysis and glycosylation, the protein migrates to 23-25 kDa (long chain A), 35-40 kDa (chain B) and 50-60 kDa (long chain A&chain B) based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • PLAU/uPA (active Form), His, Cynomolgus
    • PLAU/uPA (active Form), His, Cynomolgus

    Immobilized PLAU/uPA (active form), His, Cynomolgus, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Human uPAR, hFc Tag with the EC50 of 21.4ng/ml determined by ELISA.

  • PLAU/uPA (active Form), His, Cynomolgus
    • PLAU/uPA (active Form), His, Cynomolgus

    The purity of PLAU/uPA (active form), His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • PLAU/uPA (active Form), His, Cynomolgus
    • PLAU/uPA (active Form), His, Cynomolgus

    PLAU/uPA (active form), His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • PLAU/uPA (active Form), His, Cynomolgus
    • PLAU/uPA (active Form), His, Cynomolgus

    Cynomolgus uPAR, His Tag immobilized on CM5 Chip can bind PLAU/uPA (active form), His, Cynomolgus, His Tag with an affinity constant of 0.033 nM as determined in SPR assay (Biacore T200).


Background
Target Background Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Synonyms PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.